Sanofi Fires New Round Of Infringement Claims

By Sam Schulz

Law360, New York (June 20, 2007, 12:00 AM ET) -- Just days after suing Sandoz Inc., Sanofi-Aventis U.S. LLC stepped up its efforts to fend off generics Monday and made Israeli giant Teva Pharmaceutical Industries Ltd. the newest target of its Eloxatin patent infringement accusations.

The newest case in New Jersey district court over the colorectal cancer treatment, an oxaliplatin solution, underscores the pressure on Sanofi to protect the popular drug's patents, as well as those for other blockbuster drugs like Ambien.

According to the complaint, Teva infringed Sanofi's 5,338,874 and 5,716,988 patents when it filed...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles